General Results

Report a Concern

We welcome your feedback. Please click on one of the links below to share your experience: Patient Feedback ALERT Links Information on reporting a concern Due process and resident complaint policy
Profiles
Nuri Ozden

Nuri Ozden, MD

Internal Medicine
Not Currently Accepting New Patients
Profiles
Behzad Elahi

Behzad Elahi, MD, PhD

Neuroscience Institute
Accepting new patients
217-545-8000
Request appointment
Trial
Surgery

IMPROVE-AD

Active recruiting

Improving Outcomes in Vascular Disease – Aortic Dissection

Contact: Katie Blancett 217-545-7799
Trial
Surgery

LeAAPS

Active recruiting

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction

Contact: Katie Blancett 217-545-7799
Trial
Obstetrics and Gynecology

Collection and Banking of Blood Samples for the Study of Gynecological Diseases

Active recruiting

AOA DX is developing a blood test to detect ovarian cancer (biomarker).  The purpose of this study is to collect and store donated blood samples and associated medical data from participating subjects to help develop the ovarian cancer test.

Contact: Kathy Groesch 217-545-6671
Trial
Simmons Cancer Institute

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

Active recruiting

The purpose of the study is to test BGB-11417 (alone, with dexamethasone, and with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma who test positive for t(11;14). .

Contact: Kathy Robinson 217-545-1946
Trial
Simmons Cancer Institute

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk

Active recruiting

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).

Contact: Kathy Robinson 217-545-1946
Trial
Simmons Cancer Institute

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

Active not recruiting

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).

Contact: Kathy Robinson 217-545-1946
General Results

Cell Biology, Immunology & Cancer Biology Concentration

Welcome to the Concentration in Cell Biology, Immunology & Cancer Biology at SIU School of Medicine. Our faculty, graduate students and medical students conduct innovative research in the areas of cancer biology; therapeutic targeting; tumor immunology; stem cell biology and lineage differentiation; as well as tumor vascular and lymphatic biology. The Simmons Cancer Institute is a focal point for scientists in this concentration, fostering translation of research discoveries from the laboratory to clinic. Students in this concentration will be involved in discovery-based, forward-thinking
Subscribe to